health system, utilizing former technologists now in management or other roles, and increasing the number of shifts for the core staff. Vendor support staff members were on site during both days of the moving process, and provided the manpower and technical expertise necessary to relocate the instruments. In our case, the addition of new chemistry analyzers and a new track system coincided with the move, and enabled us to make use of the vendor staff necessary to validate the new instrumentation and automation systems. All available in-house laboratory information staff and database coordinators, as well as middleware experts from the manufacturer of the new instruments, were on site during the entirety of the process. This enabled a rapid assessment of any problems encountered during the re-establishment of the instrument interfaces. A senior manager of hospital facilities management was present throughout the move and proved invaluable. Difficulties involving the absence of a necessary power outlet and problems moving multiple pneumatic tube systems were surmounted quickly and without unnecessary delay thanks to the presence of multiple skilled contractors. Communicating with clinical staff and informing them of progress and delays was imperative, the disruptions of service in tube systems required that specimens be delivered by hand, in addition to making clinical staff aware that there would be delays in processing. The presence of senior laboratory management on site during the relocation enabled rapid decision-making, quick assessment of patient comparisons and connectivity, and provided guidance for the staff. As residents we analyzed patient comparisons after moving instruments and ensured appropriate information system connectivity, in addition to communicating the progress of the relocation with clinical staff. Our experience during this process provided invaluable knowledge of the challenges faced by laboratory medical directors. We were able to gain an understanding of the critical role and involvement of a multitude of departments, appropriate staffing, laboratory testing and the regulations involved in moving a laboratory.
health system, utilizing former technologists now in management or other roles, and increasing the number of shifts for the core staff. Vendor support staff members were on site during both days of the moving process, and provided the manpower and technical expertise necessary to relocate the instruments. In our case, the addition of new chemistry analyzers and a new track system coincided with the move, and enabled us to make use of the vendor staff necessary to validate the new instrumentation and automation systems. All available in-house laboratory information staff and database coordinators, as well as middleware experts from the manufacturer of the new instruments, were on site during the entirety of the process. This enabled a rapid assessment of any problems encountered during the re-establishment of the instrument interfaces. A senior manager of hospital facilities management was present throughout the move and proved invaluable. Difficulties involving the absence of a necessary power outlet and problems moving multiple pneumatic tube systems were surmounted quickly and without unnecessary delay thanks to the presence of multiple skilled contractors. Communicating with clinical staff and informing them of progress and delays was imperative, the disruptions of service in tube systems required that specimens be delivered by hand, in addition to making clinical staff aware that there would be delays in processing. The presence of senior laboratory management on site during the relocation enabled rapid decision-making, quick assessment of patient comparisons and connectivity, and provided guidance for the staff. As residents we analyzed patient comparisons after moving instruments and ensured appropriate information system connectivity, in addition to communicating the progress of the relocation with clinical staff. Our experience during this process provided invaluable knowledge of the challenges faced by laboratory medical directors. We were able to gain an understanding of the critical role and involvement of a multitude of departments, appropriate staffing, laboratory testing and the regulations involved in moving a laboratory. Background: Aberrant drug test results are a significant occurrence among patients undergoing chronic opioid therapy. Monitoring medication compliance and drug abuse is common practice in chronic pain management clinics, as it can increase patient prescription drug compliance and reduce illicit drug abuse. There is also interest in directly quantifying certain glucuronide metabolites to better inform clinicians about drug metabolism in their patients. However, most current pain management panels do not directly quantitate glucuronide metabolites due to several technical difficulties associated with their quantification. Despite widely available immunoassays, chromatography-mass spectrometry-based methods are considered the gold standard for therapeutic drug monitoring due to their high sensitivities and specificities. Herein, we describe the validation of a fast, convenient ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/ MS) assay to simultaneously quantify 35 prescription drugs, drugs of abuse, and related glucuronides and other metabolites, in human urine by single sample injection. Methods: A total of 35 analytes were chosen for quantification or semi-quantification based on clinician feedback. Analytes consisted of prescription and illicit opioids, benzodiazepines, and stimulants, including parent compounds and glucuronidated and non-glucuronidated metabolites. Urine samples were prepared by diluting with water and spiking it with deuterated internal standards. No enzymatic hydrolysis, analyte extraction, or sample purification were required. Analytes were separated by reverse-phase UPLC and quantified by positive-mode electrospray ionization and collision-induced dissociation mass spectrometry. Assay validation followed Food and Drug Administration (FDA) bioanalytical guidelines. Results: The assay was validated in accordance with current FDA recommendations and the anticipated testing clinical context. Total analytical run time was 5 min. All analytes demonstrated acceptable linearity (r2 > .99), accuracy (DEV <15%), precision (CV <15%), and clinically relevant analytical ranges (1-2,000 ng/mL, depending on analyte). Stability and matrix effects were also assessed for each analyte. Assay performance for each analyte was compared to either reference laboratory or previously validated in-house methods. Conclusions: A convenient and fast UPLC-MS/MS assay for simultaneously monitoring 35 clinically relevant analytes was developed and validated for use in chronic pain management at a tertiary medical center. Advantages of this assay include (1) simple sample preparation, which avoids extraction and hydrolysis steps, (2) higher-throughput multi-analyte detection including glucuronide metabolite quantification, and (3) a potential reduction in send-out confirmation testing by avoiding the use of immunoassays.
